Literature DB >> 27589330

Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.

Elizabeth A Neuner1, Jason C Gallagher2.   

Abstract

Carbapenem-Resistant Enterobacteriaceae (CRE) are an emerging healthcare crisis. Infections due to CRE are associated with high morbidity and mortality, especially in critically ill patients. Due to the multi-drug resistant nature of these infections only limited treatment options are available. Antimicrobials that have been described for the treatment of CRE infections include carbapenems, polymyxins, fosfomycin, tigecycline, aminoglycosides, and ceftazidime-avibactam. Given the limited treatment options it is imperative the pharmacokinetic and pharmacodynamics (PK-PD) characteristics of these agents are considered to optimize treatment regimens. This review will focus on the PK-PD challenges of the current treatment options for CRE infections.

Entities:  

Keywords:  carbapenem-resistant Enterobacteriaceae; pharmacodynamics; pharmacokinetics

Mesh：

Substances：

Year:  2016        PMID： 27589330      PMCID： PMC5477717          DOI： 10.1080/21505594.2016.1221021

Source DB:  PubMed          Journal:  Virulence        ISSN： 2150-5594            Impact factor:   5.882


  112 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

2.  Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

Authors:  Antonio T Freire; Vasyl Melnyk; Min Ja Kim; Oleksiy Datsenko; Oleksandr Dzyublik; Felix Glumcher; Yin-Ching Chuang; Robert T Maroko; Gary Dukart; C Angel Cooper; Joan M Korth-Bradley; Nathalie Dartois; Hassan Gandjini
Journal:  Diagn Microbiol Infect Dis       Date:  2010-10       Impact factor: 2.803

3.  Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.

Authors:  D M Livermore; S Mushtaq; M Warner; J-C Zhang; S Maharjan; M Doumith; N Woodford
Journal:  J Antimicrob Chemother       Date:  2010-11-14       Impact factor: 5.790

4.  Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.

Authors:  Roberto Imberti; Maria Cusato; Paola Villani; Livio Carnevale; Giorgio A Iotti; Martin Langer; Mario Regazzi
Journal:  Chest       Date:  2010-06-17       Impact factor: 9.410

5.  First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.

Authors:  Romney M Humphries; Shangxin Yang; Peera Hemarajata; Kevin W Ward; Janet A Hindler; Shelley A Miller; Aric Gregson
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

6.  In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.

Authors:  Catharine C Bulik; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

Review 7.  Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.

Authors:  Oren Zusman; Tomer Avni; Leonard Leibovici; Amos Adler; Lena Friberg; Theodouli Stergiopoulou; Yehuda Carmeli; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

8.  Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Authors:  D Plachouras; M Karvanen; L E Friberg; E Papadomichelakis; A Antoniadou; I Tsangaris; I Karaiskos; G Poulakou; F Kontopidou; A Armaganidis; O Cars; H Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

9.  Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae.

Authors:  K F Anderson; D R Lonsway; J K Rasheed; J Biddle; B Jensen; L K McDougal; R B Carey; A Thompson; S Stocker; B Limbago; J B Patel
Journal:  J Clin Microbiol       Date:  2007-06-20       Impact factor: 5.948

10.  Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study.

Authors:  Nikolaos Markou; Marizoza Fousteri; Sophia L Markantonis; Basilios Zidianakis; Despina Hroni; Eleni Boutzouka; George Baltopoulos
Journal:  J Antimicrob Chemother       Date:  2012-07-12       Impact factor: 5.790
View more
  9 in total

1.  Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know.

Authors:  David van Duin
Journal:  Virulence       Date:  2017-04-12       Impact factor: 5.882

Review 2.  The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms.

Authors:  Ann Marie Porreca; Kaede V Sullivan; Jason C Gallagher
Journal:  Curr Infect Dis Rep       Date:  2018-05-05       Impact factor: 3.725

Review 3.  Rapid Susceptibility Testing Methods.

Authors:  Kenneth P Smith; James E Kirby
Journal:  Clin Lab Med       Date:  2019-06-12       Impact factor: 1.935

4.  Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin.

Authors:  Takayuki Katsube; Roger Echols; Toshihiro Wajima
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

Review 5.  Carbapenem Therapeutic Drug Monitoring in Critically Ill Adult Patients and Clinical Outcomes: A Systematic Review with Meta-Analysis.

Authors:  Sharon Lechtig-Wasserman; Hans Liebisch-Rey; Nicolas Diaz-Pinilla; Jhosep Blanco; Yuli-Viviana Fuentes-Barreiro; Rosa-Helena Bustos
Journal:  Antibiotics (Basel)       Date:  2021-02-10

6.  Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.

Authors:  Nicholas Rebold; Taylor Morrisette; Abdalhamid M Lagnf; Sara Alosaimy; Dana Holger; Katie Barber; Julie Ann Justo; Kayla Antosz; Travis J Carlson; Jeremy J Frens; Mark Biagi; Wesley D Kufel; William J Moore; Nicholas Mercuro; Brian R Raux; Michael J Rybak
Journal:  Open Forum Infect Dis       Date:  2021-12-09       Impact factor: 3.835

7.  Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.

Authors:  Luzelena Caro; David P Nicolau; Jan J De Waele; Joseph L Kuti; Kajal B Larson; Elaine Gadzicki; Brian Yu; Zhen Zeng; Adedayo Adedoyin; Elizabeth G Rhee
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

Review 8.  How to manage KPC infections.

Authors:  Matteo Bassetti; Maddalena Peghin
Journal:  Ther Adv Infect Dis       Date:  2020-05-14

9.  Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections.

Authors:  Pratik Bhagunde; Parul Patel; Mallika Lala; Kenny Watson; William Copalu; Ming Xu; Pooja Kulkarni; Katherine Young; Matthew L Rizk
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-10-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.